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Background: In Kawasaki disease (KD), it has been clinically and experimentally reported that
post-inﬂammatory vascular remodeling would induce the development of arteriosclerosis or
early onset of atherosclerosis in the future. The effects of 3-hydroxy-3-methylglutaryl coenzyme
A (HMG-CoA) reductase inhibitors on continuous vascular remodeling late after Kawasaki disease
were clinically evaluated.
Patients and methods: We enrolled and treated a total of 11 KD patients (age range, 7—25
years) with ﬂuvastatin (0.5—0.7mg/kg/day) for 12 months. All of them had signiﬁcant coro-
nary aneurysmal or stenotic lesions and more than 3 of the following 5 abnormal ﬁndings:
reduced %ﬂow-mediated dilatation (%FMD), reduced urinary NOx, elevated high-sensitivity C-
reactive protein (hs-CRP), reduced urinary 8-isoprostane, and elevated brachial-ankle pulse
wave velocity (baPWV; control, 1400 cm/s).
Results: A statistically signiﬁcant improvement was observed in each biomarker after ﬂu-
vastatin treatment: %FMD, from 9.29% (3.41)% to 10.55% (3.27)% (p = 0.003) after 3 months;
NOx/creatinine (cre), from 1.16 (0.54)mol/mg cre to 1.30 (0.50)mol/mg cre (p = 0.038)
after 12 months; baPWV, from 1175.4 (277.3) cm/s to 1031.8 (155.6) cm/s (p = 0.009) after 3
months; hs-CRP, from 0.073 (0.035)mg/dl to 0.028 (0.014)mg/dl (p = 0.0002) after 3 months;
and 8-iso/cre, from 751.8 (241.8) pg/mg cre to 660.0 (198.5) pg/mg cre (p = 0.018) after 3
months. No adverse events were clinically observed in the patients.
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Conclusions: The results of this study suggested that HMG-CoA reductase inhibitors are use-
ful as an alternative therapeutic strategy for stabilizing continuous post-inﬂammatory vascular
remodeling that results in the development of arteriosclerosis late after KD or early onset of
.





























































































tem (Waters Corp., Milford, MA, USA) to determine the
concentration of urinary NOx [32]. The levels of urinary
NOx were standardized with those of urinary cre (NOx/cre;atherosclerosis in the future
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awasaki disease (KD) is an acute febrile disorder of
nknown etiology that mainly affects infants and young chil-
ren [1—3]. It is characterized by systemic vasculitis. The
ost common and serious clinical feature is the involve-
ent of the coronary arteries, which results in aneurysmal
hanges that can lead to the development of stenotic lesions
r myocardial ischemia associated with late mortality [4,5].
ven in transient dilatated and regressed coronary lesions,
ntimal thickening associated with arteriosclerotic changes
as been detected by imaging using two-dimensional
chocardiography, magnetic resonance imaging (MRI), and
ntravascular ultrasonography with virtual histology [6,7].
n addition, even in adolescents and adults who did not
ave coronary lesions, endothelial dysfunction [determined
y measuring the coronary ﬂow reserve, ﬂow-mediated
ilatation (FMD) of the brachial artery, and urinary NOx],
ersistent inﬂammation [determined by measuring high-
ensitivity C-reactive protein (hs-CRP) levels], and oxidative
tress were noted [8—11]. Moreover, there is clinical and
xperimental evidence [12,13] in support of a history of
D as a risk factor for the early onset or progression of
therosclerosis [14,15]. Therefore, it is necessary to develop
new therapeutic strategy for preventing the early onset or
rogression of atherosclerosis in patients with a history of
D.
Recently, it has been demonstrated that 3-hydroxy-
-methylglutaryl coenzyme A (HMG-CoA) reductase
nhibitors, which act through both cholesterol-dependent
nd cholesterol-independent mechanisms, signiﬁcantly
educe the likelihood of major coronary events [16—18].
ecent studies have also revealed that HMG-CoA reductase
nhibitors have an anti-inﬂammatory effect, and improve
ndothelial dysfunction and oxidative stress, which are
igniﬁcant markers of the early progression of atheroscle-
osis [19—22]. Therefore, these inhibitors could prevent
he progression of arteriosclerosis or atherosclerosis in KD
atients, but this is yet to be studied.
In this study, we aimed to evaluate the therapeutic
ffects of HMG-CoA reductase inhibitors on the prevention
f continuous post-inﬂammatory vascular remodeling result-
ng in the development of arteriosclerosis in KD patients.
o do so, we treated KD patients with HMG-CoA reduc-
ase inhibitors late after the onset of KD and examined the
hanges in various biochemical and physiological biomark-
rs associated with endothelial function, arterial stiffness,
ascular wall inﬂammation, and oxidative stress.
atients and methodsn this study, we enrolled 11 Japanese patients with KD
mean (SD) age, 14.5 (6.1) years; range, 7—25 years]





[han 3 of the following 5 abnormal ﬁndings: reduced %FMD,
ow urinary NOx levels, increased brachial-ankle pulse wave
elocity (baPWV), increased hs-CRP levels, and high uri-
ary 8-isoprostane levels, compared with the age-matched
ontrol values previously reported (%FMD, 14.4± 3.2%; uri-
ary NOx, 1.22± 0.92mol/mg creatinine (cre); baPWV,
1400 cm/s; hs-CRP, 0.035± 0.05mg/dl) [11]. The inter-
al between the onset of KD and the start of this study
as 4—22 years [mean (SD), 12.4 (6.0) years]. All the
atients met the clinical criteria for KD and had acute or
ealed coronary artery lesions, as documented by coro-
ary angiography. These patients were followed up at our
niversity hospital. They received anticoagulant therapy,
ut none of them received angiotensin-converting enzyme
nhibitors, angiotensin receptor blockers, beta-adrenergic
lockers, calcium channel antagonists, or nitrates. All the
ubjects were non-smokers and had no history of hyper-
ension, hyperglycemia, or hypercholesterolemia. All the
ubjects continued to take anti-thrombotic drugs, but they
ere advised not to consume too much vitamins C and E
nd polyphenols; they were also instructed not to perform
trenuous exercises on the day before the examination. This
tudy was approved by the ethics committee of our univer-
ity. Written informed consent to the study protocol was
btained from all the patients and their parents.
The study protocol was as follows. We measured the
FMD and urinary NOx as markers of endothelial func-
ion [23—26], baPWV as a marker of arterial stiffness
27—29], hs-CRP as a marker of vascular wall inﬂam-
ation [30,31], and urinary 8-isoprostane as a marker
f oxidative stress [25,26]. These parameters were mea-
ured before treatment and 3, 6, and 12 months after
nitiating the administration of the HMG-CoA reductase
nhibitor ﬂuvastatin (0.5—0.7mg/kg/day). The dose of ﬂu-
astatin was controlled so that the total serum cholesterol
evel was maintained above 120mg/kg in each subject,
ince this is the required level of cholesterol in the
ody. All examinations were performed in the morn-
ng.
Samples of urine and venous blood were collected in bot-
les, immediately aliquoted, and stored at −80 ◦C. %FMD was
easured using high-resolution ultrasonography with a 12.0-
Hz linear-array transducer (Vivid 3; GE Medical Systems,
airﬁeld, CT, USA) as previously described [11]. Capillary
lectrophoresis was performed using a Quanta 4000 sys-nits, mol/mg cre). baPWV was measured using a nonin-
asive volume plethysmographic technique (form PWV/ABI;
olin Co., Komaki, Japan) [27,33], and hs-CRP was measured
sing the latex agglutination reaction. Urinary 8-isoprostane
34—36] was measured using ELISA, and its levels were stan-
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Table 1 Clinical proﬁle of the patients.








1 F 3 10 ANm (RCA) AN, LS (RCA) A, W, D —
2 M 1 13 ANm (B-CA) AN, LS
(RCA, LCA)
A, W —
3 M 2 22 ANl (B-CA) REC (RCA),
AN (LCA)
A, D —
4 M 1 7 ANm (RCA) ANm (RCA) A, W —
5 M 2 21 ANl (B-CA) REC (RCA),
AN (LCA)
A, W, D —
6 F 4 9 ANm (B-CA) AN (LCA), LS
(RCA)
A, W —
7 F 3 13 ANm (RCA) AN, LS (RCA) A —
8 M 3 25 ANl (B-CA) REC (RCA),
AN (LCA)
A, W —
9 M 1 8 ANm (LCA) AN, LS (LCA) A, P —
10 M 2 18 ANl (B-CA) REC (RCA),
AN (LCA)
A, W —



























sCAL, coronary artery lesion; AN, aneurysm; ANm, medium-sized a
left coronary artery; B-CA, coronary arteries of both sides; LS,
dipyridamole.
dardized with those of urinary cre (8-iso/cre; units, pg/mg
cre).
Statistical analysis
All values are expressed as mean (SD) unless otherwise
speciﬁed. All data analyses were performed using the SPSS
13.0J software (SPSS, Chicago, IL, USA). The values obtained
before and after ﬂuvastatin treatment were statistically
analyzed using the paired t-test. A p-value of less than 0.05
was considered statistically signiﬁcant.
Results
The clinical proﬁle of the subjects is shown in Table 1.
All the subjects had some form of coronary artery lesion,
including stenotic lesions, but none had a history of
myocardial ischemia. The electrocardiogram ﬁndings and
left ventricular wall motion, studied using two-dimensional
echocardiography, were normal in all the subjects. Before
the ﬂuvastatin treatment, the subjects had signiﬁcantly
low %FMD [p < 0.05; 9.29% (3.41)% vs. 14.4% (3.2)%], and
had signiﬁcantly high hs-CRP [p < 0.05; 0.073 (0.035)mg/dl
vs. 0.016 (0.006)mg/dl] and 8-iso/cre [p < 0.05; 751.8
(241.8) pg/mg cre vs. 512.2 (272.2) pg/mg cre] compared to
the controls. There were no statistically signiﬁcant differ-
ences between the subjects and controls in NOx/cre [1.16
(0.54)mol/mg cre vs. 1.22 (0.92)mol/mg cre] and baPWV
[1175.4 (277.3) cm/s vs. 1161 (114) cm/s].%FMD and urinary NOx as markers of endothelial
function
The values of %FMD changed during the 12-month ﬂu-





tsm; ANl, large-sized aneurysm; RCA, right coronary artery; LCA,
lized stenosis; REC, recanalization; A, aspirin; W, warfarin; D,
igniﬁcantly increased from 9.29% (3.41%) before the ini-
iation of treatment to 10.55% (3.27%) (p = 0.003) after 3
onths, 10.68% (3.24%) (p = 0.0003) after 6 months, and
0.87% (3.11%) (p = 0.0004) after 12 months (Fig. 1). For
rinary NOx/cre ratio, there were no statistically signiﬁ-
ant differences between the value before the treatment
1.16 (0.54)mol/mg cre], 3 months [1.20 (0.54)mol/mg
re] and 6months [1.24 (0.45)mol/mg cre] after the treat-
ent. However, the NOx/cre signiﬁcantly increased to 1.30
0.50)mol/mg cre after 12 months (Fig. 2).
aPWV as a marker of arterial stiffness
aPWV changed during the 12-month ﬂuvastatin treatment
eriod (Table 2 and Fig. 3); it signiﬁcantly decreased from
175.4 (277.3) cm/s before treatment initiation to 1031.8
155.6) cm/s (p = 0.009) after 3 months, 1014 (161.9) cm/s
p = 0.001) after 6 months, and 1027.2 (166.4) cm/s
p = 0.001) after 12 months.
s-CRP as a marker of inﬂammation
he values of serum hs-CRP changed during the 12-month
uvastatin treatment period (Table 2 and Fig. 4). The hs-CRP
alue before ﬂuvastatin treatment was 0.073 (0.035)mg/dl,
hich is signiﬁcantly higher (p < 0.05) than our repeated
alue of 0.016 (0.006)mg/dl in age-matched KD patients
n = 20) without any cardiac lesions. The hs-CRP values
igniﬁcantly decreased to 0.028 (0.014)mg/dl (p = 0.0002)
fter 3 months, 0.024 (0.007)mg/dl (p = 0.0002) after
months, and 0.020 (0.007)mg/dl (p = 0.0001) after 12
onths of ﬂuvastatin treatment. These reductions in serum
s-CRP remained steady during the 12-month ﬂuvastatin
reatment.
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Table 2 Changes in the parameters of the subjects before and after ﬂuvastatin treatment.
Parameters Before After initiating ﬂuvastatin treatment p-Value at 12 months
3 months 6 months 12 months
% FMD 9.29 ± 3.41 10.55 ± 3.27* 10.68 ± 3.24* 10.87 ± 3.11* 0.0004
NOx/cre 1.16 ± 0.54 1.20 ± 0.54 1.24 ± 0.45 1.30 ± 0.50* 0.038
baPWV 1175.4 ± 277.3 1031.8 ± 155.6* 1014.5 ± 161.9* 1027.2 ± 166.4* 0.001
hs-CRP 0.073 ± 0.003 0.028 ± 0.014*0.0 −0.024 ± 0.007* 0.020 ± 0.007* 0.0001
8-iso/cre 751.8 ± 241.8 660.0 ± 198.5* 626.3 ± 181.8* 609.1 ± 183.8* 0.001
Total cholesterol 171.1 ± 13.1 144.2 ± 8.6* 143.6 ± 9.8* 144.1 ± 7.8* 0.00001
Results are expressed as mean (SD). %FMD, percent ﬂow-mediated dilatation; NOx/cre, NOx/creatinine; baPWV, pulse wave velocity of
the brachial artery; hs-CRP, high-sensitivity C-reactive protein; 8-iso/cre, 8-isoprostane/creatinine.
* p < 0.05 vs. the pre-treatment values.
Figure 1 Changes in percent ﬂow-mediated dilatation (%FMD) in subjects treated with ﬂuvastatin for 12 months. Bar shows mean
(SD). *p < 0.05 vs. the pre-treatment values.
Figure 2 Changes in urinary NOx/creatinine (cre) values in subjects treated with ﬂuvastatin for 12 months. Bar shows mean (SD).
*p < 0.05 vs. the pre-treatment values.










tFigure 3 Changes in the pulse wave velocity of the brachial
Bar shows mean (SD). *p < 0.05 vs. the pre-treatment values.
8-Iso/cre as a marker of oxidative stress
The 8-iso/cre ratio changed during the 12-month ﬂu-
vastatin treatment period (Table 2 and Fig. 5). The
8-iso/cre value before ﬂuvastatin treatment was 751.8
(241.8) pg/mg cre; this value is signiﬁcantly higher (p < 0.05)
than our reported value of 512.2 (272.2) pg/mg cre in
age-matched KD patients (n = 20) without any cardiac
lesions. After ﬂuvastatin treatment was initiated, the
8-iso/cre ratio signiﬁcantly decreased to 660.0 (198.5)
(p = 0.018) after 3 months, 626.3 (181.8) (p = 0.009)





Figure 4 Changes in the serum high-sensitivity C-reactive prote
months. Bar shows mean (SD). *p < 0.05 vs. the pre-treatment valuesy (baPWV) in subjects treated with ﬂuvastatin for 12 months.
erum cholesterol as a marker of ﬂuvastatin dose
he values of total serum cholesterol changed during the 12-
onth ﬂuvastatin treatment period (Table 2 and Fig. 6). The
otal serum cholesterol level signiﬁcantly decreased from
71.1 (13.1)mg/dl to 144.2 (8.63)mg/dl (p = 0.000014) after
months, 143.6 (9.84)mg/dl (p = 0.000043) after 6 months,
nd 144.1 (7.85)mg/dl (p = 0.000012) after 12 months of ﬂu-
astatin treatment. We controlled the dose of ﬂuvastatin not
o decrease total serum cholesterol value under 120mg/dl.
dditionally, during the ﬂuvastatin treatment, none of the
atients had any signiﬁcant symptom including leg pain, or
bnormal laboratory data in the hepatic function and CK.
in (hs-CRP) values in subjects treated with ﬂuvastatin for 12
.




























vigure 5 Changes in the urinary 8-isoprostane/creatinine (8-i
hows mean (SD). *p < 0.05 vs. the pre-treatment values.
iscussion
n the present study, we have evaluated the effects of ﬂu-
astatin administration on %FMD, urinary NOx (both markers
f vascular endothelial function), baPWV (marker of arte-
ial stiffness), hs-CRP (marker of chronic inﬂammation), and
rinary 8-isoprostane (marker of oxidative stress). A signif-
cant improvement was observed in each of these markers
fter the administration of ﬂuvastatin. We selected these
arkers because (1) recently, a markedly advanced molecu-
ar biological method was used to analyze the pathogenic
echanism of arteriosclerosis or atherosclerosis, and the
bove markers were found to be associated with vascular
emodeling and the subsequent development of arterioscle-




igure 6 Changes in the total blood cholesterol in subjects treated
s. the pre-treatment values.re) ratio in subjects treated with ﬂuvastatin for 12 months. Bar
idely used to assess the clinical conditions or treatment of
therosclerosis in adult patients with obesity, hypertension,
yperlipidemia, or diabetes mellitus [26—32,37].
It has been suggested that KD eventually leads the devel-
pment of post-inﬂammatory arteriosclerosis [2,3]. Further,
t was reported that arteriosclerosis develops early at the
ite of the morphological changes by clinically apparent
oronary aneurysms [4,5,38]. However, these are studied
nly in patients with giant aneurysms. The functional and
iological states of chronic vascular lesions can be investi-
ated with a recently developed method.We evaluated blood ﬂow and current ﬂuctuations of
he coronary artery with thermodilution and a Doppler
uidewire, respectively. Even in patients with no appar-
nt coronary arterial lesions, very small vascular lesions or










































REffect of statin on continuous post-inﬂammatory vascular re
disorders in coronary artery vasodilatation were persisting.
Moreover, a functional abnormality was found in the sys-
temic vascular endothelium [8—10]. We have also reported
the risk of early onset of arteriosclerosis in patients with
changes in the vascular endothelium, oxidative stress, and
persisting inﬂammation in the chronic phase of KD [11].
Thereafter, several studies have indicated the persis-
tence of functional disorders and inﬂammation in the
chronic phase of KD.
Intimal hypertrophy associated with arteriosclerosis has
been detected in coronary vessels with the help of diagnostic
imaging such as intravascular ultrasonography and MRI; the
hypertrophy normalized after temporary enlargement of the
vessels [6,7,39,40].
These ﬁndings indicate that vasculitis associated with
KD can potentially develop into arteriosclerosis over a long
period of time. It therefore follows that controlling the
development of blood vessel disorders into arteriosclero-
sis is important for improving long-term prognosis of KD.
However, no treatment strategy to this effect has been
established yet.
In recent years, strategies to prevent the development
of arteriosclerosis in adults with conditions such as hyper-
tension, diabetes mellitus, obesity, and hyperlipidemia
have been studied extensively. In these studies, HMG-CoA
reductase inhibitors were shown to have favorable clini-
cal effects. They decrease the serum cholesterol level by
inhibiting HMG-CoA reductase at the rate-controlling step
of cholesterol synthesis; they have therefore been used as
therapeutic agents for hyperlipidemia in clinical practice.
Since then, HMG-CoA reductase inhibitors have been proven
to have different pharmacological activities such as anti-
inﬂammatory and anti-oxidative activities, and to improve
vascular endothelial function [16,17,19—22,41]. Therefore,
HMG-CoA reductase inhibitors have attracted much atten-
tion as drugs for arteriosclerosis.
It has been reported that even in adolescent and young
children, coronary risk factors such as diabetes or hyper-
cholesterolemia lead to vascular endothelial dysfunction
and oxidative stress resulting in arteriosclerotic changes. It
has also been reported that the endothelial function was
improved by controlling these factors.
However, for children, there are few reports that HMG-
CoA reductase inhibitors are effective directly against
these risk factors. HMG-CoA reductase inhibitors’ pleiotropic
effects for adults have been licensed, so now we can expect
their clinical application for children [42—45].
Since the pathological mechanism of the development
of inﬂammatory atherosclerotic lesions in infants and young
individuals has not been completely elucidated, there is no
effective method for assessing the function of blood vessels
in KD patients. Therefore, the efﬁcacy of HMG-CoA reduc-
tase inhibitors has not been studied by clinical investigation.
We developed an animal model of KD, which is similar
to the model of vasculitis in juvenile rabbits, and clearly
demonstrated the anti-inﬂammatory activities of HMG-CoA
reductase inhibitors against the progress of acute vasculitis
[46,47]. The present clinical investigation was conducted
on the basis of the results obtained in these animal experi-
ments.
We found a signiﬁcant improvement in the levels of all
ﬁve markers after ﬂuvastatin administration. This effect waseling late after Kawasaki disease 251
ound as early as 3 months later and continued during the
2 months of administration. We found that the continuous
ost-inﬂammatory vascular remodeling, which results in the
evelopment of arteriosclerosis, was signiﬁcantly stabilized
y the administration of HMG-CoA reductase inhibitors late
fter KD. From these observations, it is anticipated that they
ay also be effective for the early stabilization of coronary
esions during the acute to convalescent periods of KD. More-
ver, they probably suppress the long-term development of
otential atherosclerosis. We believe that to improve the
ong-term prognosis of blood vessel disorders in KD patients,
therapeutic approach using HMG-CoA reductase inhibitors
ight be an alternative to the present strategies such as
nticoagulant therapy.
Because the sample size was small, the present study
as a preliminary investigation with limited indications.
lthough it was possible to suppress the development of
ost-inﬂammatory arteriosclerosis by administering HMG-
oA reductase inhibitors, further studies are necessary to
etermine the indications or administration periods of the
rug in KD patients receiving concurrent medication.
The primary pharmacological activity of HMG-CoA reduc-
ase inhibitors is to decrease the blood cholesterol level.
holesterol plays an important role in biological functions
nd is absolutely necessary in the body. Keeping this in
ind, particularly in the case of children and pubertal
ndividuals, we adjusted the dose of HMG-CoA reductase
nhibitors so that the level of blood cholesterol remained
bove 120mg/dl in all the patients [48—51]. No signiﬁ-
ant adverse reactions or complications occurred during the
tudy; however, we have not investigated several parame-
ers such as optimum dosage, time of administration, and
ype of HMG-CoA reductase inhibitor. Large-scale clinical
nvestigations will be required to determine these factors.
onclusion
n this study, we found that HMG-CoA reductase inhibitors
tabilized endothelial dysfunction, arterial stiffness, oxida-
ive stress, and chronic vascular inﬂammation in KD patients
ith coronary artery lesions. Therefore, we think that HMG-
oA reductase inhibitors have the potential to prevent
he development of post-inﬂammatory arteriosclerosis late
fter KD and early onset of atherosclerosis in the future.
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